ERBB2 and endometrial carcinoma: In advanced HER2-positive endometrial carcinoma, the addition of trastuzumab, a mAb targeting the extracellular domain of HER2, to standard chemotherapy with carboplatin and paclitaxel has demonstrated clinical benefit [113].